The co-primary endpoints were the proportion of patients at week 12 with at least a 75 % reduction in the PASI score from baseline ( PASI75 response ) and the proportion of patients achieving a PGA score of `` clear '' or `` almost clear '' ( PGA response ) , analysed in the full analysis set ( all patients who were randomised and received at least one dose of study drug ) .